Endosense company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Acquired | Acquired

Total Raised




About Endosense

Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company developed the use of contact-force measurement in catheter ablation with the development of the TactiCath, a force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

Endosense Headquarter Location

Chemin du Grand-Puits 42 Meyrin

Geneva, 1217,


+ 41 22 306 19 60

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Endosense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endosense is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,449 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Endosense Patents

Endosense has filed 15 patents.

patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Fiber optics, Surgery, Medical equipment, Digestive system


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Fiber optics, Surgery, Medical equipment, Digestive system



Latest Endosense News

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

Oct 8, 2020

Madrid, Spain, October 6th 2020: Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time, announces today the closing of a €14 million Series E financing, co-led by Asabys Partners (through the fund Sabadell Asabys Health Innovation Investments), VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital. Several of the investors joining this round were investors in Endosense, a company in the same space acquired by Abbott (St. Jude Medical) in 2013 for more than USD 300 million. Medlumics was founded in Madrid in 2009 and is led by James Greene (CEO) who has long-term experience in the industry both as a serial entrepreneur in the MedTech industry and as an executive in global medical device players. AblaView® is the first imaging system to assess the treatment of Atrial Fibrillation by ablation, allowing the operator to directly assess both the positioning of the ablation catheter on the myocardium and the continuity and transmurality of the ablation. The cardiac Ablation catheter market was $3.9b in 2019, with only 4,4% of people diagnosed being treated using ablation technology. A limiting factor for adoption of the ablation technique remains the high rate of recurrence due to lack of lesion transmurality (ablation of the myocardium in all its depth) and lack of lesion continuity, leaving gaps of untreated tissues. The AblaView® technology tackles this problem, guiding practitioners and confirming therapy success in real time. Ablaview® is fully compatible with the RF ablation catheters that are already on the market. The financing will allow Medlumics to complete the preclinical development of its technology and obtain first in human clinical data. “Medlumics optically guided ablation technology provides electrophysiologists direct information without surrogates to make real time decisions critical for successful ablation resulting in reducing AF recurrence rate. Recent preclinical studies were very successful and demonstrated AblaView®’s ability to directly assess catheter to tissue contact, stability with high sensitivity, and continuous progress of the ablation of the tissue. Using photonics, clinicians will soon directly assess lesion progression and continuity in real time and subsequently locate and ablate gaps with precision. I thank new and existing investors for the trust and support in our company as we will be able to march from preclinical to clinical proof soon”, commented James Greene, CEO of Medlumics SL. Josep Ll. Sanfeliu, Managing Partner at Asabys Partners, said: “We have been following Medlumics for years. We were immediately excited by the last developments of the company and are thrilled to collaborate with a very experienced team at the maturation of a technology that could impact the life of hundreds of thousands of patients worldwide”. Diego Braguglia, Managing Partner at VI Partners, stated: “Medlumics AblaView® will promote RF ablation to the next level, providing real time information on the quality of the ablations. This represents a quantum leap in AF treatment. Patients outcome will be dramatically impacted by the ability of clinicians to follow on real time the progression of the ablations and its quality. We are very honoured and excited to be part of this endeavour.” © 2018 VI Partners AG

  • When was Endosense founded?

    Endosense was founded in 2003.

  • Where is Endosense's headquarters?

    Endosense's headquarters is located at Chemin du Grand-Puits 42, Geneva.

  • What is Endosense's latest funding round?

    Endosense's latest funding round is Acquired.

  • How much did Endosense raise?

    Endosense raised a total of $100.6M.

  • Who are the investors of Endosense?

    Investors of Endosense include St. Jude Medical, Neomed Management, Initiative Capital Romandie, Andera Partners, Ysios Capital Partners and 7 more.

  • Who are Endosense's competitors?

    Competitors of Endosense include Upromise, AutoGenomics, Foundation Medicine, Signature Diagnostics, Crescendo Bioscience and 8 more.

You May Also Like


Diagnoplex is leveraging its molecular platform capabilities to develop a colorectal cancer (CRC) screening test. Diagnoplex's lead product, Colox, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called "host response", and are involved at the earliest stages of tumor formation.

Cellpoint Diagnostics

CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

Dilon Technologies

Dilon Technologies delivers clinically useful imaging and intra operative systems appropriate for early disease diagnosis and surgical applications. Dilon's cornerstone product, the Dilon Molecular Breast Imaging System, is a high-resolution, compact camera, and is available as a single or dual head camera. The Dilon cameras have been optimized to perform Molecular Breast Imaging (MBI/BSGI) procedure that aids in early detection of breast cancer.

Akonni Biosystems Logo
Akonni Biosystems

Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.


CS-Keys, LLC is creating cancer-specific biomarkers using advanced protein chemistry technologies (proteomics). The company is developing a new series of diagnostics to detect the occurrence or re-occurrence of cancer leading to more effective individualized treatment strategies for primary and metastatic disease, with an initial focus on breast cancer.

Daktari Diagnostics Logo
Daktari Diagnostics

Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.